Biophytis Company Overview
About Biophytis
Biophytis (EPA:ALBPS), (NASDAQ:BPTS) is a biotechnology firm focused on developing drug candidates to slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19. The company's portfolio primarily targets sarcopenia and macular degeneration, conditions that significantly affect the elderly population. Biophytis conducts its work with the aim to bring innovative therapies from bench to bedside by navigating through the complex processes of clinical development and regulatory approval. The firm's dedication to combating age-related diseases underscores its commitment to improving the quality of life for an aging global population.
Snapshot
Operations
Products and/or services of Biophytis
- Sarconeos (BIO101) for sarcopenia and severe respiratory failure due to COVID-19.
- Macuneos (BIO201) for Dry Age-related Macular Degeneration (AMD).
- Development of therapeutics targeting age-related diseases including obesity.
- Research on neuromuscular diseases treatment options.
- Exploration of therapies for metabolic disorders.
- Investigations into treatments for cardiovascular diseases.
Biophytis executive team
- Mr. Stanislas Veillet Ph.D.Chairman of the Board & CEO
- Mr. Nicolas FellmannChief Financial Officer
- Mr. Waly Dioh Ph.D.Chief Clinical Operating Officer
- Dr. Pierre J. DildaChief Scientific Officer
- Dr. Rene LafontScientific Advisor & Member of Scientific Advisory Board
- Dr. Rob van Maanen FFPM, M.B.A., M.D.Chief Medical Officer
- Mr. Edouard BiethChief Business Officer
- Ms. _ TeylanFinancial Controller